Sign in
CompletedNo phase

Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder

Key facts

Who runs it
HAII corp.ltd
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
96 people enrolled
Started
14 Aug 2023
Ended
24 Jul 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Software as a Medical device
Record updated
19 September 2024

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • People can participate in this clinical trial only if following criteria are met
  • Adults aged 19 years or older with a high school diploma or higher
  • Disease groups according to the criteria below:; A person diagnosed with Generalized Anxiety Disorder (DSM-5 (ICD-10) code: 300.02 (F41.1)); Those who are classified as moderate or severe with 10 points or more through GAD-7; Those taking prescription drugs related to generalized anxiety disorder
  • A group of disorders with generalized anxiety disorder, or a group of disorders with worry that is a major symptom of generalized anxiety disorder in any of the following criteria:; Those suffering from other anxiety disorders such as panic disorder and social anxiety disorder; Those suffering from major depressive disorder accompanied by worry, the main symptom of generalized anxiety disorder
  • A person who fully understands the purpose, contents, and process of the clinical trial, agrees to participate, and signs the consent form in handwriting

Who cannot take part

  • Receiving cognitive behavioral therapy for anxiety, depression or mood disorders, or participating in such therapy in the past 3 months
  • In case of psychiatric symptoms or history (including schizophrenia, psychosis, bipolar disorder, epilepsy)
  • In case of brain damage, cognitive impairment, or neurological disease
  • Having a substance and alcohol use disorder
  • If any of the following criteria is applicable, the person cannot participate in this clinical trial
  • Those who cannot read the consent form
  • Those who are inexperienced in using smartphones
  • In case of intellectual disability
  • Suicidal intent, suicidal ideation, or self-injurious behavior in the past 6 months
  • Those who are registered in other clinical studies
  • Other investigators judged that the conduct of this clinical trial was inappropriate

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The investigators propose to develop and adapt 'ANZEILAX' smartphone app specifically for individuals with Generalized anxiety disorder. The study will measure the therapeutic effects and safety of 'ANZEILAX' on symptoms of anxiety using pre- and post-treatment scores for generalized anxiety disorder and other physical, emotional, and cognitive symptoms of anxiety

The 2 groups in the trial

  • Experimental GroupTreatment being tested

    The general treatment of the standard treatment method and the test device that provides self-talk training based on acceptance and commitment therapy (ACT) are used concurrently for 10 weeks.

    Treatment: Software as a Medical device

  • Control GroupNo study treatment, for comparison

    Treatment as usual (TAU) is a standard treatment for 10 weeks, which is the clinical trial period.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single Blind, Parallel Arm, Single Institution Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder
Publications
Record updated
19 September 2024